<DOC>
	<DOCNO>NCT01373047</DOCNO>
	<brief_summary>The purpose study collect data safety potential effectiveness 2nd generation designer T cell deliver hepatic circulation patient liver metastasis express CEA tumor marker . Designer T cell prepare collect white blood cell participant , modify cell laboratory recognize tumor antigen , CEA . These modified cell give back participant attack kill tumor cell . The investigator hypothesize regional delivery designer T cell directly hepatic artery minimize systemic toxicity optimize change therapeutic effect .</brief_summary>
	<brief_title>CEA-Expressing Liver Metastases Safety Study Intrahepatic Infusions Anti-CEA Designer T Cells</brief_title>
	<detailed_description>T cell power destroy malignant cell certain condition , demonstrate rare spontaneous remission cancer . However , endogenous T cell response cancer fail vast majority patient tolerogenic condition within liver may pose additional immunologic barrier intrahepatic metastasis . The investigator modify patient T cell kill malignant cell base expression tumor antigens use antibody-defined recognition . The investigator achieve prepare chimeric IgCD28TCR gene mammalian expression vector yield `` designer T cell '' normal patient cell . Prior study model system demonstrate recombinant IgCD28TCR could direct modify T cell respond antigen target IL2 secretion , cellular proliferation , cytotoxicity - hallmark effective , self-sustaining immune response . The present trial test regional infusion anti-CEA designer T cell , give via hepatic artery use percutaneous approach . This intra-patient dose escalation trial , patient receive three dos course six week . Doses 10^8 , 10^9 10^10 modify T cell . Patients monitor safety response . Patients on-study one month dosing .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Histologically confirm diagnosis CEA+ adenocarcinoma liver metastases Liver metastasis must CEAexpressing demonstrate elevated serum CEA level ( â‰¥10ng/ml ) immunohistochemistry biopsy specimen Failure least one line standard systemic chemotherapy unresectable liver disease Measurable liver disease ( &gt; 1.0 cm CT MRI ) Extrahepatic disease acceptable limited lung and/or abdominal lymph node At least 18 year age Able understand sign inform consent Life expectancy great four month Good performance status ( PS 01 ) Pregnancy Serious medical condition include limited liver , cardiopulmonary , renal disease Patients history portal hypertension , cirrhosis , hepatitis , radiographic evidence cirrhosis Concurrent malignancy Use systemic steroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>liver metastasis</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>regional therapy</keyword>
	<keyword>T cell</keyword>
</DOC>